Exclusive Summary

• Features a high-barrier powder-liquid dual-chamber design (Ready-to-Use system) for bedside mixing, effectively preventing secondary contamination and saving nursing preparation time.
• Listed in the WHO Essential Medicines List as a first-line treatment for prevalent severe infections like pneumonia and meningitis, guaranteeing massive and stable clinical demand.
• Scheduled for an EU GMP inspection in Q4 2026, assuring top-tier international quality compliance and allowing partners to front-run registration in regulated and emerging markets.
• Delivers an upgraded, premium drug delivery system while leveraging China's integrated API-to-finished product supply chain to offer superior pharmacoeconomic value compared to originators and similar specialized dosage forms.